CD274 and non-small cell lung carcinoma: In fact, multiple trials have demonstrated that patients with advanced NSCLC who are eligible for ICI therapy survive longer, with 5-year survival rates ranging from 16% to 43%, depending on PD-L1 expression levels and the ICI line of treatment (2).